Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu

Journal of Immunotherapy

Volumn 31, Issue 6, 2008, Pages 537-544

  Pratesi, Graziella ^a,b   Petrangolini, Giovanna ^a   Tortoreto, Monica ^a   Addis, Alessandro ^c   Zunino, Franco ^a   Calcaterra, Claudia ^d   Merlo, Andrea ^b   Tagliabue, Elda ^b   Menard, Sylvie ^b   Balsari, Andrea ^d  

^a Preclinical Chemotherapy and Pharmacology Unit   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Department of Clinical Science ^*  (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Animal model; Gemcitabine; HER 2 neu; Pancreatic cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; RITUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER INHIBITION; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG SCREENING; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 48549083052     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31817c37ff     Document Type: Article

References (36)

1. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays. 1998;20:41-48.
2. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 1997;410:83-86.
3. Dougall WC, Qian X, Peterson NC, et al. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene. 1994;9:2109-2123.
4. Mohsin SK, Weiss HL, Gutierrez MC, et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol. 2005;23:2460-2468.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659-1672.
7. Disis ML, Cheever MA. HER-2/neu protein: a target for antigenspecific immunotherapy of human cancer. Adv Cancer Res. 1997;71: 343-371.
8. Clynes R, Ravetch JV. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity. 1995;3:21-26.
9. Spiridon CI, Guinn S, Vitetta ES. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res. 2004;10: 3542-3551.
10. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000;6: 443-446.
11. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94:259-267.
12. Gennari R, Me' nard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 2004;10:5650-5655.
13. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639-2648.
14. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
15. Goldstein D, Carroll S, Apte M, et al. Modern management of pancreatic carcinoma. Intern Med J. 2004;34:475-481.
16. Kimura K, Sawada T, Komatsu M, et al. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res. 2006;12:4925-4932.
17. Stoecklein NH, Luebke AM, Erbersdobler A, et al. Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. J Clin Oncol. 2004;22:4737-4745.
18. Novotny J, Petruzelka L, Vedralova J, et al. Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma. 2001;48:188-191.
19. Grant AG, Duke D, Hermon-Taylor J. Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice. Br J Cancer. 1979;39: 143-151.
20. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer I. 1990;82:1107-1112.
21. United Kingdom Co-ordinating Committee on Cancer Res. (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (edn. 2). Br J Cancer. 1998;77:1-10.
22. Pratesi G, Petrangolini G, Tortoreto M, et al. Therapeutic synergism of gencitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res. 2005;65: 6388-6393.
23. Pratesi G, Manzotti C, Tortoreto M, et al. Effects of 5-FU and cis- DDP combination on human colorectal tumor xenografts. Tumori. 1989;75:60-65.
24. Spiridon CI, Ghetie MA, Uhr J, et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res. 2002;8:1720-1730.
25. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11:4898-4904.
26. Barok M, Isola J, Palyi-Krekk Z, et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007;6:2065-2072.
27. Niwa R, Sakurada M, Kobayashi Y, et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res. 2005;11:2327-2336.
28. Lustig HJ, Bianco C. Antibody-mediated cell cytotoxicity in a defined system: regulation by antigen, antibody, and complement. J Immunol. 1976;116:253-260.
29. Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/ neu. Exp Hematol. 1999;27:1533-1541.
30. Vernimmen D, Gueders M, Pisvin S, et al. Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer. 2003;89:899-906.
31. Salzberg M, Borner M, Bauer JA, et al. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer. 2006;42:2660-2661.
32. Hirsch FR, Langer CJ. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. Semin Oncol. 2004;31:75-82.
33. Green SK, Karlsson MC, Ravetch JV, et al. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res. 2002; 62:6891-6900.
34. Safran H, Iannitti D, Ramanathan R, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest. 2004;22:706-712.
35. Kayahara M, Nagakawa T, Ueno K, et al. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72: 2118-2123.
36. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg. 1996;171: 118-124.